The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
The Wolverine Stack pairs two compounds that address different bottlenecks in the same process. BPC-157 restores the local signaling environment at the injury site. TB-500 mobilizes the systemic cellular response. Neither bottleneck, solved alone, produces optimal healing. Solving both together is the mechanistic argument for the stack.
Tissue healing after injury — whether acute trauma, surgical repair, or chronic overuse — proceeds through a sequence of overlapping phases: initial hemostasis, inflammation (cytokine signaling, immune cell recruitment), proliferation (fibroblast migration, collagen deposition, angiogenesis), and remodeling (collagen organization, scar maturation). Two common failure modes interrupt this sequence in practice: (1) inadequate local angiogenesis and growth factor signaling at the injury site — the wound bed lacks the vascular supply and stimulatory environment for effective repair; (2) inadequate systemic recruitment of repair-competent cells — the circulating pool of progenitor cells, endothelial cells, and anti-inflammatory signals fails to mobilize efficiently to the injury.
BPC-157 addresses the first failure mode. In animal models, BPC-157 upregulates the expression of growth hormone receptors at the injury site, stimulates local VEGF production and angiogenesis, promotes fibroblast and tendon cell migration via FAK (focal adhesion kinase) pathway activation, and suppresses local inflammatory cytokines. The result: the injury site becomes a more permissive signaling environment for tissue reconstruction. TB-500 addresses the second failure mode. As a fragment of Thymosin Beta-4, TB-500 promotes actin polymerization (essential for cell migration), stimulates systemic endothelial cell and progenitor cell mobilization, and has anti-inflammatory activity via NF-kB suppression. The result: more repair-competent cells arrive at the injury site from the systemic circulation.
THE CENTRAL TENSION
The Wolverine Stack is the most widely used peptide healing combination in community history — thousands of user logs, years of accumulated experience, clinics prescribing it, physicians writing protocols for it. The mechanistic rationale is coherent: two compounds, two different mechanisms, two different phases of the healing cascade, administered together. And yet: BPC-157 has 36 published studies — 35 preclinical, 1 clinical. TB-500 + BPC-157 together have zero published studies of any kind. Zero. The combination that community members have been running for years has never been tested in even a mouse model as a combination. The stackGrade is C — not because the combination evidence is weak, but because the combination evidence does not exist. This chapter documents the mechanistic logic, the individual evidence bases, and what thousands of users have reported — with honest evidence framing throughout.
The community protocol has been refined over years of shared experience. It is pragmatic, not pharmacologically derived. Every element of the timing and cycle structure below is community-convention — not based on a human pharmacokinetic or clinical trial.
Protocol Element
Recommended
Notes
BPC-157 dose
250-500 mcg/day SubQ
Lower end for smaller individuals or as conservative start; 500 mcg most common community dose for musculoskeletal injury
TB-500 loading dose
5-10 mg/week × 4 weeks (split: 2.5-5 mg twice weekly)
Loading phase builds systemic Tβ4 pool; twice-weekly spacing is practical; not pharmacokinetically derived
TB-500 maintenance dose
2-5 mg/week (once or twice weekly) after loading
Maintenance after initial 4-week loading; ongoing support for continued cycle
BPC-157 route
SubQ near injury site OR oral (gut only)
Near-injury for musculoskeletal; oral only for gut healing; oral does not provide systemic musculoskeletal effects
TB-500 route
SubQ anywhere — abdomen preferred
Not injection-site dependent; systemic distribution is the mechanism
Combined injection
Can inject both in same session (different syringes, different sites)
No evidence against same-session administration; mixing in same syringe not recommended (stability unknown)
Pre-blended vial
10 mg BPC-157 + 10 mg TB-500 per vial (common community format)
Convenient but fixes the 1:1 ratio; reduces independent dose control — see Section 5.2
Cycle length
4-8 weeks total
4 weeks minimum to assess effect; 8 weeks common for chronic injury recovery
Rest period
4+ weeks off between cycles
Community convention; no washout data; allows assessment of sustained effects
Timing (BPC-157)
Before bed or between meals (avoid with large meal)
Daily consistency more important than specific timing
Timing (TB-500)
Any time of day; 2× weekly spacing
Not time-sensitive; systemic compound
The market has converged on blended 10mg/10mg vials (10 mg BPC-157 + 10 mg TB-500 per lyophilized vial) as the most convenient Wolverine Stack format. Advantages: single reconstitution, single injection, lower cost than two separate vials, simplified protocol. Disadvantages: fixed 1:1 ratio locks both compounds to the same dose escalation — if you want to run 500 mcg/day BPC-157 with a lower TB-500 dose, or adjust one component independently, a blended vial cannot accommodate this. Stability of the blend during reconstitution and storage is not formally published — community experience suggests no degradation over standard BAC water reconstitution periods, but this is not confirmed by independent analysis. For users who want independent dose control or need to adjust components separately (e.g., higher BPC-157 for acute injury with lower TB-500 maintenance), separate vials are preferable.
Indication
BPC-157
TB-500
Cycle Notes
Acute injury (first 2 weeks post-trauma/surgery)
500 mcg/day SubQ near injury
10 mg/week loading (5mg × 2)
Start immediately; acute phase requires maximum signaling environment
Ongoing injury recovery (weeks 3-8)
250-500 mcg/day
5 mg/week (2.5 mg × 2)
Transition from loading; sustain signaling while tissue rebuilds
Chronic overuse/maintenance
250 mcg/day or 5×/week
2-5 mg/week
Lower dose; ongoing support; assess need for continuing every 4 weeks
Gut healing (standalone or add-on)
500 mcg-1 mg oral (gut only); BPC-157 for systemic also
Standard SubQ
Oral BPC-157 addresses gut mucosa locally; TB-500 adds systemic anti-inflammatory
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide (15 amino acids) derived from a naturally occurring sequence in human gastric juice protein BPC. It has never been isolated in its exact 15-AA form from human tissue — it is synthetic, not a natural peptide. The sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Stable in gastric acid (unlike most peptides), which is the basis for the oral route for gut-specific applications.
Parameter
BPC-157 Detail
Evidence grade (individual)
C — Animal replicated; Grade E for specific community-derived claims
FDA status
Category 1 (as of 2023 FDA guidance); not approved; historically in compounding gray zone
Human RCT
One retrospective case series (n=12; knee pain; open-label) — the only published human clinical data as of 2025 Vasireddi systematic review
Primary mechanism
VEGF upregulation (local angiogenesis); growth hormone receptor expression ↑; FAK pathway (fibroblast migration); NF-kB suppression (anti-inflammatory); gut mucosal protection via nitric oxide pathway
Routes
SubQ (primary for systemic/musculoskeletal); intramuscular; oral (gut-specific; absorbed locally in GI, not systemic)
Community dose in Wolverine Stack
250-500 mcg/day SubQ; or 250 mcg twice daily
Oral dose (gut only)
500 mcg-1 mg/day oral; does not reach systemic circulation at therapeutic levels; gut-targeted only
Evidence context
35 preclinical studies (tendon, ligament, muscle, bone, gut, nerve) from predominantly one research group (Sikiric et al., Zagreb); one published human clinical dataset; 2025 HSS Journal systematic review (Vasireddi et al.) concluded Level IV-V evidence, no clinical safety data
TB-500 is a synthetic heptapeptide (7 amino acids) corresponding to the actin-binding domain of Thymosin Beta-4 (Tβ4) — specifically amino acids 17-23 of the parent molecule: Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ). This fragment distinction is pharmacologically important: most of the mechanism research, and all of the human clinical data (Phase 2 trials for wound healing, a 2025 Phase 2b trial in acute MI), is on the full Thymosin Beta-4 parent compound. Whether the TB-500 fragment recapitulates the full parent molecule's pharmacology is not established in comparative controlled trials — it is assumed to, because the actin-binding domain is considered responsible for TB4's cell migration effects.
Parameter
TB-500 Detail
Evidence grade (individual)
C — animal replicated for parent compound (Thymosin Beta-4); E — community consensus for TB-500 fragment specifically
FDA status
Research only; not approved; parent compound Thymosin Beta-4 has had investigational drug status in Phase 2 trials
Human RCT (TB-500 fragment)
Zero — no human RCT specifically for TB-500 (LKKTETQ fragment)
Human RCT (Thymosin Beta-4 parent)
Phase 1 safety in healthy volunteers (IV); Phase 2b in acute MI (NCT05984134; n=90; completed enrollment; results pending); Phase 2 in pressure/venous ulcers (positive results for wound healing)
Primary mechanism
Actin polymerization and cell migration (actin-sequestering via G-actin binding); systemic endothelial cell and progenitor cell mobilization; NF-kB anti-inflammatory; myocardial progenitor cell activation (cardiac repair animal models)
The fragment uncertainty
TB-500 (LKKTETQ) contains the actin-binding domain only. The full Thymosin Beta-4 (43 amino acids) also signals through other pathways. Clinical trials use the full protein. Whether the 7-AA fragment is equivalent, superior, or inferior for healing applications is not established.
Community dose in Wolverine Stack
Loading: 5-10 mg/week (split into 2 injections) × 4 weeks. Maintenance: 2-5 mg/week × ongoing cycle.
Route
SubQ only; the systemic mechanism means local injection near injury is not necessary or superior — inject conveniently (abdomen, thigh)
The combination is mechanistically non-redundant. BPC-157 and TB-500 operate on different cellular targets, different molecular pathways, and different phases of the healing cascade.
Dimension
BPC-157
TB-500
Synergy
Primary cell target
Fibroblasts, tendon cells, gut mucosal cells (local)
Endothelial cells, progenitor cells (systemic circulation)
Local signaling environment + circulating cell supply = complete repair response
Angiogenesis
Strong: VEGF upregulation, new capillary growth at injury site
Moderate: endothelial cell migration via actin regulation
BPC-157 provides the angiogenic signal; TB-500 delivers the endothelial cells to respond to it
Cell migration
FAK pathway — fibroblast and tendon cell directed migration
Actin polymerization — universal cell migration facilitator; promotes progenitor cell trafficking
FAK (local) + actin (systemic) = migration at and to the injury site
Anti-inflammatory
NF-kB suppression (local inflammatory cytokine reduction)
NF-kB suppression (systemic inflammatory reduction)
Convergent anti-inflammatory from both directions
Collagen synthesis
Stimulates fibroblast collagen production (local)
Promotes matrix remodeling via cell migration support (systemic)
Early collagen signal (BPC-157) + cell delivery for ongoing synthesis (TB-500)
Route preference
SubQ near injury OR oral (gut-specific)
SubQ anywhere — systemic distribution; not injection-site dependent
Complementary routes: BPC-157 near injury, TB-500 at convenient SubQ site
Timing relevance
Acute: immediately beneficial at injury site; chronic: ongoing signaling
Loading phase beneficial to saturate systemic pool; maintenance phase for ongoing support
BPC-157 daily for constant local signal; TB-500 loading then maintenance for sustained circulating levels
Stack grade: C. This reflects the combination specifically — not the individual components. The combination of BPC-157 + TB-500 has zero published studies of any kind. Grade C is assigned based on the individual animal evidence for each component, not on any combination data that does not exist.
The Peptigrity analysis (April 2026) identified this precisely: the 2025 systematic review of BPC-157 found 36 published studies (35 preclinical, 1 clinical). For the combination of BPC-157 + TB-500 as a stack, there are zero published studies — no preclinical combination studies, no clinical trials, no safety data on the pairing. The Wolverine Stack is the most widely used peptide combination with no direct research to support or refute it.
This does not mean the combination is unlikely to work — the mechanistic case is coherent and the complementary mechanisms are non-redundant. It means the specific dose ratios, timing, cycle lengths, and combination-specific safety profile are unknown. It means that whether the combination produces additive, synergistic, or merely additive-at-best effects has never been tested. And it means that any interaction between the two compounds at the molecular or systemic level has never been characterized.
Evidence Layer
BPC-157
TB-500
Wolverine Stack (Combination)
Human RCTs
0 (1 retrospective case series, n=12)
0 for TB-500 fragment; Phase 2b for parent Thymosin Beta-4
0
Animal preclinical
35 published studies (tendon, ligament, gut, bone, nerve, muscle)
Robust animal data for parent Thymosin Beta-4 across multiple injury models
0 combination studies
Combination-specific
—
—
Zero published studies of any kind
C (animal), E (community)
C (parent compound animal), E (fragment community)
C — assigned from individual component animal evidence
Human safety data
One IV pilot, n=2 (Lee et al., 2024); no measurable biomarker changes
Phase 1 in healthy volunteers (IV parent compound); generally safe
No combination safety data
The Wolverine Stack is one of the most accessible peptide protocols in terms of cost. Both compounds are widely available from research peptide vendors. Quality verification is the primary sourcing challenge.
Format
Approximate Cost (USD)
Duration
Notes
BPC-157, 5 mg vial (separate)
$25-60 per vial
~10-20 days at 500 mcg/day
Price varies significantly by vendor quality tier; research grade vs pharma grade
TB-500, 5 mg vial (separate)
$30-70 per vial
~1-2 weeks at loading dose
TB-500 more expensive per mg than BPC-157 generally
Blended 10mg/10mg Wolverine vial
$60-120 per vial
~20 days at 500 mcg BPC/day + TB-500 schedule
Most cost-efficient option if fixed 1:1 ratio acceptable
Full 8-week standard protocol
$150-400 total
One complete cycle
Highly variable; research chemical vendors substantially cheaper than clinic markup
Clinic/physician-prescribed
$300-800+ for protocol
One cycle
Often includes pharmaceutical-grade preparation, consultation, monitoring
Both BPC-157 and TB-500 are available from research peptide vendors as lyophilized powder requiring reconstitution, and from some compounding pharmacies (with prescription, where available). Quality variables: HPLC purity (should be ≥98% for either compound); mass spectrometry verification of correct molecular weight (BPC-157 MW ~1419 Da; TB-500/LKKTETQ MW ~799 Da); endotoxin testing (LAL test) for injectable grade — endotoxins cause fever and systemic inflammation when injected; sterility testing. A valid COA (Certificate of Analysis) should include HPLC purity, mass spec confirmation of molecular identity, and ideally endotoxin (LAL) test result. HPLC purity alone is necessary but not sufficient — a 99% pure compound with wrong sequence identity or endotoxin contamination is still unsafe to inject.
Common sourcing red flags for both compounds: pre-reconstituted liquid solutions (peptides in solution degrade faster than lyophilized powder; pre-made solutions suggest corners cut in preparation); COA showing only HPLC purity without mass spec identity; unusually low prices (<$15 for 5mg vial of either compound typically signals underdosing or impure synthesis); no lot-specific COA (vendor provides only generic COA not specific to the batch you are purchasing). BPC-157 is among the most commonly counterfeited research peptides due to its popularity — purchase only from vendors with third-party batch-specific testing documentation.
ACTIVE MALIGNANCY — BOTH COMPOUNDS
BPC-157's strong VEGF upregulation (angiogenic mechanism) and TB-500's Thymosin Beta-4-class progenitor cell mobilization both carry theoretical risk of supporting tumor vascularization and growth in the context of active cancer. Active malignancy is a caution for both components and for the stack. This is not a hard stop in the same category as GHK-Cu (which has a harder angiogenic mechanism signal), but it is a meaningful caution. Physician consultation is mandatory before using the Wolverine Stack in any individual with active or recent cancer.
Thousands of users have documented Wolverine Stack cycles on Reddit (r/peptides, r/Nootropics, r/PeptidesResearch) and related forums. The patterns below represent community consensus across independent reports — not controlled trial data.
Commonly reported timeline: injection site reactions (mild burning, localized redness) in first 1-2 days with BPC-157 SubQ, particularly at higher concentrations — typically resolve as technique improves; first noticeable effects at 2-3 weeks (reduced pain, improved mobility at injured site); structural recovery effects (tendon palpation improvement, range of motion increase, strength return) most noticeable at 4-8 weeks; gut-specific effects (when oral BPC-157 used) often reported within 1-2 weeks.
Consistently reported across user logs: dramatic subjective improvement in healing timeline for tendon and ligament injuries versus previous injury recovery without peptides; reduced need for NSAIDs during healing; improved sleep quality during cycles (mechanism unclear — possibly reduced pain load or direct effect); vivid dreams reported by a subset of TB-500 users (possible Thymosin Beta-4 CNS effects — not well characterized). Skeptical notes from the community: some users report minimal to no effect, particularly with lower-quality sources; outcome variability is high; users who had verifiable third-party tested sources consistently report better outcomes than those who did not.
Stack
Slug
Relationship
Added Component
GLOW Stack
glow-stack
Wolverine + GHK-Cu
Adds GHK-Cu (injectable) for collagen remodeling and copper-mediated gene expression layer; cosmetic + healing combined
KLOW Stack
klow-stack
GLOW + KPV
Adds KPV (anti-inflammatory tripeptide from alpha-MSH) for gut and systemic inflammation reduction; the anti-inflammatory extension of GLOW
Gut Stack
gut-stack
BPC-157 + KPV
BPC-157 (oral) + KPV for gut-specific healing; tighter indication than Wolverine; oral route focus
Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). BPC-157 in orthopaedic injury models: systematic review. HSS Journal. [Most current systematic review; 36 studies screened (35 preclinical, 1 clinical); all human evidence Level IV-V; no clinical safety data; confirms no BPC-157 + TB-500 combination studies published.]
Sikiric P, Seiwerth S, Rucman R, et al. (2021). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. [Foundational BPC-157 mechanism review from the primary research group; gut-brain axis, healing, anti-inflammatory.]
Malinda KM, Goldstein AL, Kleinman HK. (1997). Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal. 11(6):474-481. [Foundational Tβ4 endothelial migration study; actin-sequestering mechanism; basis for TB-500 vascularization rationale.]
Smart N, Risebro CA, Melville AAD, et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 445:177-182. [Landmark Nature paper; Thymosin Beta-4 as cardiac progenitor mobilizer; systemic cell recruitment mechanism.]
NCT05984134. Phase 2b trial of recombinant Thymosin Beta-4 in acute myocardial infarction. [n=90; completed enrollment; placebo vs 0.5 and 1.0 mcg/kg; most current clinical trial for Thymosin Beta-4 parent compound; results pending.]
Lee et al. (2024). Intravenous BPC-157 pilot study. [n=2 participants; 10mg then 20mg IV; no measurable biomarker changes in cardiac, liver, kidney, thyroid, or glucose; limited but the only published human intravenous BPC-157 safety data.]
The Wolverine Stack is the most pharmacologically coherent community healing protocol in this book and simultaneously the combination with the most evidence-to-use-volume mismatch in the peptide space. It works, on available evidence — the question is in what exact form, at what doses, and for whom.
The mechanistic rationale is solid: BPC-157's local angiogenic and growth factor signaling paired with TB-500's systemic progenitor cell mobilization addresses the two primary bottlenecks in tissue healing through non-overlapping pathways. The animal evidence for each component individually is extensive — 35 preclinical BPC-157 studies, robust Thymosin Beta-4 data across multiple injury models. Thousands of community users report consistent improvement in healing timelines for tendon, ligament, and joint injuries. The evidence gap: the combination itself has never been tested in a controlled study of any kind, and neither compound has a meaningful human RCT in musculoskeletal applications. The community is ahead of the science, as it often is in the peptide space. For users who understand this — who are running a pharmacologically coherent extrapolation from animal evidence and community consensus — the Wolverine Stack represents a reasonable healing support protocol. For users expecting the validation of a prescription drug, that evidence does not yet exist.
STACK SUMMARY
Wolverine Stack: type=stack; slug=wolverine-stack; stackGrade=C. COMPONENTS: bpc-157 + tb-500. relatedStacks: glow-stack, klow-stack, gut-stack. indication: acute and chronic musculoskeletal healing; tendon/ligament/muscle/joint repair; post-surgical recovery; gut healing (with oral BPC-157). studyCounts: humanRct: 0, humanObs: 3, animal: 60+, inVitro: 40+, combinationStudies: 0. COMBINATION STUDIES: zero published studies of any kind for BPC-157 + TB-500 together. stackGrade=C is based on individual component animal evidence, not combination evidence. BPC-157 COMPONENT: synthetic pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; MW ~1419 Da); SubQ primary (musculoskeletal); oral (gut only, no systemic musculoskeletal reach); Grade C animal; 35 preclinical + 1 clinical study (n=12 retrospective); Category 1 FDA status; FDA-banned from compounding as of 2023. Role in stack: local angiogenesis, growth factor upregulation (GHR expression, VEGF), FAK fibroblast/tendon migration, NF-kB anti-inflammatory. DOSE in stack: 250-500 mcg/day SubQ. TB-500 COMPONENT: heptapeptide LKKTETQ (Tβ4 fragment aa17-23; MW ~799 Da); SubQ anywhere (systemic mechanism); Grade C for parent Thymosin Beta-4 animal data; Grade E for fragment specifically; zero human RCT for TB-500 fragment; Phase 2b for parent compound (NCT05984134). Role in stack: actin polymerization/cell migration; systemic progenitor and endothelial cell mobilization; NF-kB anti-inflammatory. DOSE in stack: loading 5-10 mg/week × 4 weeks; maintenance 2-5 mg/week. COMMUNITY PROTOCOL: 4-8 week cycle; 4-week rest minimum; BPC-157 daily SubQ near injury; TB-500 twice weekly SubQ anywhere; blended 10mg/10mg vials common but fix 1:1 ratio. INJECTION TECHNIQUE: separate syringes; separate sites; do not mix in same syringe; same-session administration fine. COST: ~$150-400 per full 8-week cycle research grade; clinic prices $300-800+. ACTIVE MALIGNANCY: caution (VEGF + progenitor cell mobilization); physician consultation required. COMMON MISTAKES: oral BPC-157 for musculoskeletal (ineffective); TB-500 at injury site (unnecessary); skipping TB-500 loading; stopping before 4 weeks; mixing in same syringe.
— End of Wolverine Stack —
THE PEPTIDE BIBLE | Wolverine Stack | For Research & Educational Purposes Only
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.